NOVA22007

Phase 3Small molecule

SSanten Inc.

NOVA22007 is one of 43 small molecule programs targeting Keratoconjunctivitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconjunctivitisActive, not recruiting

Dry Eye SyndromeActive, not recruiting

KeratoconjunctivitisPhase 3

Active, not recruiting

Dry Eye SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Dry Eye Syndrome

#DrugCompanyPhaseTrials

Aldactone

Alphagan

Cyclosporine a

1 4

Sodium Hyaluronate

Sanofi

Phase 3

1 5

Ilaris

Cosentyx

Restasis

Aurinia Pharmaceuticals

Phase 3

6 8

Cyclosporin a

Novartis

Phase 2

1 9

NOVA22007

SSanten Inc.

Phase 3

1 10

HU007

HHuons Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Completed·SSanten Inc.·Phase 2·NCT00739349·132 enrolled

Keratoconjunctivitis1 trial

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

Completed·SSanten Inc.·Phase 3·NCT01751126·169 enrolled

Dry Eye Syndrome1 trial

Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome

Completed·SSanten Inc.·Phase 3·NCT00814515·482 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NOVA22007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NOVA22007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NOVA22007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Santen Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSanten Inc.

NOVA22007

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Keratoconjunctivitis1 trial

Dry Eye Syndrome1 trial

References

Drug Info

Quick Facts

Related News